Table 2.
Subject group | Cases | Controls | P for cases versus controls | ||
---|---|---|---|---|---|
N | 8-epiPGF2αa (pg/mg creatinine) |
N | 8-epiPGF2αa (pg/mg creatinine) |
||
Total subjects | 610 | 456 (434–479) | 610 | 402 (382–422) | <0.001 |
By smoking status | |||||
Never smokers | 116 | 248 (226–273) | 116 | 254 (231–280) | 0.743 |
Former smokers | 58 | 293 (256–335) | 58 | 222 (194–255) | 0.005 |
Current smokers | 436 | 573 (545–602) | 436 | 488 (464–512) | <0.001 |
P for current versus never smokers | <0.001 | <0.001 | P for interaction = 0.019† | ||
P for current versus former smokers | <0.001 | <0.001 | |||
P for former versus never smokers | 0.113 | 0.051 |
aGeometric means (95% confidence intervals) and P values were derived from the two-way analysis of variance with log (8-epiPGF2α) as dependent variable and lung cancer status and smoking status as the two main factors with the following covariates: age, year of biospecimen collection, neighborhood of residence at baseline, level of education and body mass index (kg/m2).
†Two-sided P for interaction between smoking status (current versus never) and lung cancer status on log (8-epiPGF2α).